Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated
for 1st or 2nd line anticancer therapy
Observational
Observational Model: Cohort, Time Perspective: Prospective
Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
36 months
No
Pfizer CT.gov Call Center
Study Director
Pfizer
Slovakia: Ethics Commitee of the Bratislava Selgf-Governing Region
A6181185
NCT00873210
May 2009
November 2011
Name | Location |
---|